Alnylam Pharmaceuticals, Inc. — Patent Portfolio
1 drug with active patents · 13 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Alnylam Pharmaceuticals' portfolio is moderately exposed, with a significant cliff year in 2027 and $700 million in revenue at risk.
Portfolio overview Alnylam Pharmaceuticals has a relatively small portfolio of 5 drugs, with 1 drug having patents and a total of 13 US patents. The company's patents are mostly active, with no expired patents, and have an average vulnerability score of 64. The portfolio consists of 0 ironclad patents and 2 vulnerable patents. Notably, the company has no biologics in its portfolio.
Cliff calendar In 2027, 1 drug will lose exclusivity, including Onpattro. This marks a significant cliff year for the company. Additionally, the company will face a total of 1 drugs losing exclusivity in 2027.
Most exposed drugs Onpattro is the top drug facing near-term loss of exclusivity, with an earliest active patent expiry date of 2027-10-03, an average vulnerability score of 64, and annual revenue of $700 million. This drug has 13 patents and is a significant contributor to the company's revenue.
Biologic exclusivity Alnylam Pharmaceuticals has no biologics in its portfolio, which means it does not have any biologic exclusivity.
Strategic implications The company faces $700 million in revenue at risk in the next 5 years. To mitigate this risk, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to extend the life of its patents and maintain revenue.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Onpattro (PATISIRAN SODIUM)
Cliff 2027 · 1y-
US9364435
Vuln 75
2029-04-15
This patent protects novel, stable lipid particles for delivering and/or administering nucleic acids, such as interfering RNA.
-
US8822668
Vuln 75
2029-04-15
This patent protects novel, stable lipid particles for delivering and/or administering nucleic acids, such as interfering RNA.
-
US10240152
Vuln 68
2029-10-20
This patent protects a double-stranded ribonucleic acid (dsRNA) that targets a transthyretin (TTR) gene and methods for using it to inhibit TTR expression.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 9 patents
- Formulation 4 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Alnylam Pharmaceuticals, Inc.'s patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export